SEC Form SC 13G/A filed

2/16/21 3:46:32 PM ET

$GILD

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GILD alert in real time by email

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2 )^*

Gilead Sciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

375558103

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)

CUSIP No.

375558103

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital Research Global Investors 95-1411037
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	121,649,692
		6. SHARED VOTING POWER	0
		7. SOLE DISPOSITIVE POWER	121,672,399
		8. SHARED DISPOSITIVE POWER	0
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 121,672,399 Beneficial ownership disclaimed pursuant to Rule 13d-4
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.7%
12.	TYPE OF REPORTING PERSON IA

Item 1.
	(a)	Name of Issuer Gilead Sciences, Inc.
	(b)	Address of Issuer's Principal Executive Offices 333 Lakeside Drive, Foster City, CA 94404
Item 2.
	(a)	Name of Person Filing Capital Research Global Investors
	(b)	Address of Principal Business Office or, if None, Residence 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
	(c)	Citizenship N/A
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 375558103
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[X]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[ ]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		121,672,399 **
	(b)	Percent of Class:
		9.7%
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	121,649,692
		(ii)	shared power to vote or to direct the vote	0
		(iii)	sole power to dispose or to direct the disposition of	121,672,399
		(iv)	shared power to dispose or to direct the disposition of	0
**Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl and Capital International K.K. (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 121,672,399 shares or 9.7% of the 1,253,528,149 shares believed to be outstanding.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group. Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
Item 9.	Notice of Dissolution of Group. Not Applicable
Item 10.	Certification. By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	Capital Research Global Investors
	By: /s/ Donald H. Rolfe
	Date: February 16, 2021
	Name: Donald H. Rolfe
	Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

Get the next $GILD alert in real time by email

Recent Analyst Ratings for

$GILD

Date	Price Target	Rating	Analyst
8/19/2025	$128.00	Neutral → Outperform	Daiwa Securities
8/8/2025	$127.00	Hold → Buy	Truist
7/25/2025	$133.00	Hold → Buy	Needham
4/22/2025	$125.00	Overweight	Cantor Fitzgerald
3/4/2025	$115.00 → $132.00	Outperform	Oppenheimer
2/18/2025	$120.00	Hold → Buy	Deutsche Bank
2/13/2025	$108.00	Hold → Buy	DZ Bank
1/10/2025	$87.00 → $113.00	Equal-Weight → Overweight	Morgan Stanley

More analyst ratings

SEC Form SC 13G/A filed

2/16/21 3:46:32 PM ET

$GILD

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GILD alert in real time by email

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2 )^*

Gilead Sciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

375558103

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

CUSIP No.

375558103

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital Research Global Investors 95-1411037
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	121,649,692
		6. SHARED VOTING POWER	0
		7. SOLE DISPOSITIVE POWER	121,672,399
		8. SHARED DISPOSITIVE POWER	0
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 121,672,399 Beneficial ownership disclaimed pursuant to Rule 13d-4
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.7%
12.	TYPE OF REPORTING PERSON IA

Item 1.
	(a)	Name of Issuer Gilead Sciences, Inc.
	(b)	Address of Issuer's Principal Executive Offices 333 Lakeside Drive, Foster City, CA 94404
Item 2.
	(a)	Name of Person Filing Capital Research Global Investors
	(b)	Address of Principal Business Office or, if None, Residence 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
	(c)	Citizenship N/A
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 375558103
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[X]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[ ]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		121,672,399 **
	(b)	Percent of Class:
		9.7%
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	121,649,692
		(ii)	shared power to vote or to direct the vote	0
		(iii)	sole power to dispose or to direct the disposition of	121,672,399
		(iv)	shared power to dispose or to direct the disposition of	0
**Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl and Capital International K.K. (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 121,672,399 shares or 9.7% of the 1,253,528,149 shares believed to be outstanding.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group. Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
Item 9.	Notice of Dissolution of Group. Not Applicable
Item 10.	Certification. By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	Capital Research Global Investors
	By: /s/ Donald H. Rolfe
	Date: February 16, 2021
	Name: Donald H. Rolfe
	Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

Get the next $GILD alert in real time by email

Recent Analyst Ratings for

$GILD

Date	Price Target	Rating	Analyst
8/19/2025	$128.00	Neutral → Outperform	Daiwa Securities
8/8/2025	$127.00	Hold → Buy	Truist
7/25/2025	$133.00	Hold → Buy	Needham
4/22/2025	$125.00	Overweight	Cantor Fitzgerald
3/4/2025	$115.00 → $132.00	Outperform	Oppenheimer
2/18/2025	$120.00	Hold → Buy	Deutsche Bank
2/13/2025	$108.00	Hold → Buy	DZ Bank
1/10/2025	$87.00 → $113.00	Equal-Weight → Overweight	Morgan Stanley

More analyst ratings

SEC Form SC 13G/A filed

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2 )*

SIGNATURE

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $GILD

SEC Form SC 13G/A filed

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2 )*

SIGNATURE

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $GILD

$GILD Analyst Ratings

Gilead Sciences upgraded by Daiwa Securities with a new price target

Gilead Sciences upgraded by Truist with a new price target

Gilead Sciences upgraded by Needham with a new price target

$GILD Insider Trading

Chairman & CEO O'Day Daniel Patrick covered exercise/tax liability with 4,949 shares and converted options into 10,427 shares, increasing direct ownership by 0.92% to 601,203 units (SEC Form 4)

Interim Corp Controller & CAO Wilfong Diane E. converted options into 921 shares and covered exercise/tax liability with 338 shares, increasing direct ownership by 1% to 46,259 units (SEC Form 4)

EVP, Corporate Affairs & GC Telman Deborah H converted options into 1,315 shares and covered exercise/tax liability with 634 shares, increasing direct ownership by 2% to 43,402 units (SEC Form 4)

$GILD Press Releases

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

$GILD SEC Filings

SEC Form N-PX filed by Gilead Sciences Inc.

Gilead Sciences Inc. filed SEC Form 8-K: Leadership Update

SEC Form 13F-HR filed by Gilead Sciences Inc.

$GILD Insider Purchases

Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

$GILD FDA approvals

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

$GILD Leadership Updates

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

$GILD Large Ownership Changes